Coronavirus (COVID-19) Update
AmerisourceBergen and our global businesses are highly engaged during the ongoing spread of the novel COVID-19 “Coronavirus."

August 3, 2016

US Bioservices has once-daily VIEKIRA XR in stock

VIEKIRA XR was approved by the U.S. Food and Drug Administration on July 25, 2016 as a once-daily, extended-release co-formulation of the active ingredients in VIEKIRA XR (ombitasvir, paritaprevir, and ritonavir tablets; dasabuvir tablets) and is for the treatment of patients with chronic genotype 1 (GT1) hepatitis C virus (HCV) infection, including those with compensated cirrhosis (Child-Pugh A). VIEKIRA XR is not for people with decompensated cirrhosis.